Predict your next investment

AFT Pharmaceuticals company logo
HEALTHCARE | Pharmaceuticals / Drugs
aftpharm.com

See what CB Insights has to offer

Founded Year

1997

About AFT Pharmaceuticals

AFT Pharmaceuticals develops, licenses, and sells pharmaceutical products.

AFT Pharmaceuticals Headquarter Location

Level 1 129 Hurstmere Road

Auckland, 0622,

New Zealand

+64 0800423823

Latest AFT Pharmaceuticals News

Korea approves 1st acetaminophen, ibuprofen compound injection Maxigesic

Sep 3, 2021

Korea approves 1st acetaminophen, ibuprofen compound injection Maxigesic 바로가기 기자명 Shim Hyun-tai 닫기 A compound injection of acetaminophen plus ibuprofen recently received regulatory approval in Korea on Monday, marking the first landing of a unique double-action formulation for fast and effective pain relief. KB Pharm’s received regulatory approval for the first acetaminophen plus ibuprofen compound injection, Maxigesic, in Korea. The Ministry of Food and Drug Safety (MFDS) approved KB Pharm to supply Maxigesic, the compound injection for relieving pain, in the nation on Monday. Regulators authorized Maxigesic use in adults who immediately needs administration due to pain and those who have no other routes of administration but require short-term treatment of moderate to severe pain. Maxigesic is an intravenous injection that combines two non-narcotic analgesics, 1000 milligrams of acetaminophen and 300 milligrams of ibuprofen. The drug is the first pharmaceutical product that contains both acetaminophen and ibuprofen in Korea. In Korea, acetaminophen and ibuprofen compounds developed by Hanmi Pharmaceutical could not receive regulatory approval in 2017. Also, in May, MFDS revealed that classifying the compound drug as an over-the-counter drug and giving permission was not appropriate. Maxigesic was originally developed by AFT Pharmaceuticals in New Zealand and sold as an over-the-counter drug but converted the use to manage moderate to severe pain after surgery. KB Pharm, an affiliate of Chong Kun Dang, secured exclusive domestic development and marketing rights for Maxigesic by signing a deal with AFT Pharmaceuticals in November 2018. The contract will last for 15 years, beginning from the first date of sale. Acetaminophen and ibuprofen, which make up Maxigesic, are the most widely used substances for reducing fever and pain. According to a phase 3 clinical trial conducted by AFT Pharmaceuticals on 276 adult patients who complained of moderate to severe pain after a bunionectomy, Maxigesic showed significant pain relief within 10 minutes after administration. As a compound injection, the drug demonstrated a superior pain-killing effect than a single administration of acetaminophen or ibuprofen drug with fewer cardiovascular and gastrointestinal side effects. AFT Pharmaceuticals took advantage of the excellent performance and submitted for approval in 21 countries worldwide, including major European countries and Australia. It is also taking steps to receive support from the U.S. Food and Drug Administration (FDA) through its Belgium partner Hyloris Pharmaceuticals. “Non-narcotic analgesic injection market still has a great unmet demand,” KB Pharm official said. “We will expand our share in the analgesic field by introducing a compound injection of substances widely used for killing pain and fever in Korea.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

AFT Pharmaceuticals Patents

AFT Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Hepatotoxins
  • Phenols
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/5/2013

1/14/2020

Analgesics, Hepatotoxins, Morphinans, Phenols, Opioids

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/5/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/14/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Analgesics, Hepatotoxins, Morphinans, Phenols, Opioids

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

AFT Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AFT Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.